PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On November 9, 2017, PhaseRx, Inc. (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2017. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information furnished to this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, and such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press release dated November 9, 2017*|
* This exhibit is furnished to Item 2.02 and shall not be deemed to be “filed.”
PHASERX, INC. ExhibitEX-99.1 2 tv479036_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update SEATTLE,…To view the full exhibit click
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.